Literature DB >> 8623927

Expression of retinoblastoma gene product (pRb) in mantle cell lymphomas. Correlation with cyclin D1 (PRAD1/CCND1) mRNA levels and proliferative activity.

P Jares1, E Campo, M Pinyol, F Bosch, R Miquel, P L Fernandez, M Sanchez-Beato, F Soler, A Perez-Losada, I Nayach, C Mallofré, M A Piris, E Montserrat, A Cardesa.   

Abstract

Mantle cell lymphomas (MCLs) are molecularly characterized by bcl-1 rearrangement and constant cyclin D1 (PRAD-1/CCND1) gene overexpression. Cyclin D1 is a G1 cyclin that participates in the control of the cell cycle progression by interacting with the retinoblastoma gene product (pRb). Inactivation of the Rb tumor suppressor gene has been implicated in the development of different types of human tumors including some high grade non-Hodgkin's lymphomas. To determine the role of the retinoblastoma gene in the pathogenesis of MCLs and its possible interaction with cyclin D1, pRb expression was examined in 23 MCLs including 17 typical and 6 blastic variants by immunohistochemistry and Western blot. Rb gene structure was studied in 13 cases by Southern blot. Cytogenetic analysis was performed in 5 cases. The results were compared with the cyclin D1 mRNA levels examined by Northern analysis, and the proliferative activity of the tumors was measured by Ki-67 growth fraction and flow cytometry. pRb was expressed in all MCLs. The expression varied from case to case (mean, 14.1% of positive cells; range, 1.3 to 42%) with a significant correlation with the proliferative activity of the tumors (mitotic index r = 0.85; Ki-67 r = 0.7; S phase = 0.73). Blastic variants showed higher numbers of pRb-positive cells (mean, 29%) than the typical cases (10%; P < 0.005) by immunohistochemistry and, concordantly, higher levels of expression by Western blot. In addition, the blastic cases also had an increased expression of the phosphorylated protein. No alterations in Rb gene structure were observed by Southern blot analysis. Cyclin D1 mRNA levels were independent of pRb expression and the proliferative activity of the tumors. These findings suggest that pRb in MCLs is normally regulated in relation to the proliferative activity of the tumors. Cyclin D1 overexpression may play a role in the maintenance of cell proliferation by overcoming the suppressive growth control of pRb.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8623927      PMCID: PMC1861570     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  46 in total

1.  Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data.

Authors:  P M Banks; J Chan; M L Cleary; G Delsol; C De Wolf-Peeters; K Gatter; T M Grogan; N L Harris; P G Isaacson; E S Jaffe
Journal:  Am J Surg Pathol       Date:  1992-07       Impact factor: 6.394

2.  PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma.

Authors:  C L Rosenberg; E Wong; E M Petty; A E Bale; Y Tsujimoto; N L Harris; A Arnold
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-01       Impact factor: 11.205

3.  Regulation of retinoblastoma protein functions by ectopic expression of human cyclins.

Authors:  P W Hinds; S Mittnacht; V Dulic; A Arnold; S I Reed; R A Weinberg
Journal:  Cell       Date:  1992-09-18       Impact factor: 41.582

4.  Gene rearrangement and overexpression of PRAD1 in lymphoid malignancy with t(11;14)(q13;q32) translocation.

Authors:  M Seto; K Yamamoto; S Iida; Y Akao; K R Utsumi; I Kubonishi; I Miyoshi; T Ohtsuki; Y Yawata; M Namba
Journal:  Oncogene       Date:  1992-07       Impact factor: 9.867

5.  Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins.

Authors:  H Matsushime; M E Ewen; D K Strom; J Y Kato; S K Hanks; M F Roussel; C J Sherr
Journal:  Cell       Date:  1992-10-16       Impact factor: 41.582

6.  Lack of nuclear RB protein staining in G0/middle G1 cells: correlation to changes in total RB protein level.

Authors:  H J Xu; S X Hu; W F Benedict
Journal:  Oncogene       Date:  1991-07       Impact factor: 9.867

7.  PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma.

Authors:  F Bosch; P Jares; E Campo; A Lopez-Guillermo; M A Piris; N Villamor; D Tassies; E S Jaffe; E Montserrat; C Rozman
Journal:  Blood       Date:  1994-10-15       Impact factor: 22.113

8.  Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections.

Authors:  G Cattoretti; M H Becker; G Key; M Duchrow; C Schlüter; J Galle; J Gerdes
Journal:  J Pathol       Date:  1992-12       Impact factor: 7.996

9.  A novel cyclin encoded by a bcl1-linked candidate oncogene.

Authors:  T Motokura; T Bloom; H G Kim; H Jüppner; J V Ruderman; H M Kronenberg; A Arnold
Journal:  Nature       Date:  1991-04-11       Impact factor: 49.962

10.  Characterization of a candidate bcl-1 gene.

Authors:  D A Withers; R C Harvey; J B Faust; O Melnyk; K Carey; T C Meeker
Journal:  Mol Cell Biol       Date:  1991-10       Impact factor: 4.272

View more
  12 in total

1.  A phase II, single-arm, open-label, multicenter study to evaluate the efficacy and safety of P276-00, a cyclin-dependent kinase inhibitor, in patients with relapsed or refractory mantle cell lymphoma.

Authors:  Ryan D Cassaday; Andre Goy; Suresh Advani; Purvi Chawla; Rajesh Nachankar; Mansi Gandhi; Ajay K Gopal
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2015-03-05

2.  Cyclin D1 expression and HHV8 in Kaposi sarcoma.

Authors:  M M Kennedy; S Biddolph; S B Lucas; D D Howells; S Picton; J O McGee; I Silva; V Uhlmann; K Luttich; J J O'Leary
Journal:  J Clin Pathol       Date:  1999-08       Impact factor: 3.411

3.  Retinoblastoma (RB1) gene product expression in breast carcinoma. Correlation with Ki-67 growth fraction and biopathological profile.

Authors:  C Ceccarelli; D Santini; P Chieco; M Taffurelli; M Gamberini; S A Pileri; D Marrano
Journal:  J Clin Pathol       Date:  1998-11       Impact factor: 3.411

4.  Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling.

Authors:  Kai Fu; Dennis D Weisenburger; Timothy C Greiner; Sandeep Dave; George Wright; Andreas Rosenwald; Michael Chiorazzi; Javeed Iqbal; Stefan Gesk; Reiner Siebert; Daphne De Jong; Elaine S Jaffe; Wyndham H Wilson; Jan Delabie; German Ott; Bhavana J Dave; Warren G Sanger; Lynette M Smith; Lisa Rimsza; Rita M Braziel; H Konrad Müller-Hermelink; Elias Campo; Randy D Gascoyne; Louis M Staudt; Wing C Chan
Journal:  Blood       Date:  2005-08-25       Impact factor: 22.113

5.  Elevated nuclear CCND1 expression confers an unfavorable prognosis for early stage lung adenocarcinoma patients.

Authors:  Ping Xu; Mengyang Zhao; Zhen Liu; Yiyi Liu; Yiyu Chen; Rongcheng Luo; Weiyi Fang
Journal:  Int J Clin Exp Pathol       Date:  2015-12-01

Review 6.  Cell kinetics and cell cycle regulation in lymphomas.

Authors:  L Leoncini; S Lazzi; C Bellan; P Tosi
Journal:  J Clin Pathol       Date:  2002-09       Impact factor: 3.411

7.  Retinoblastoma protein is frequently absent or phosphorylated in anaplastic large-cell lymphoma.

Authors:  George Z Rassidakis; Raymond Lai; Marco Herling; Candy Cromwell; Annette Schmitt-Graeff; L Jeffrey Medeiros
Journal:  Am J Pathol       Date:  2004-06       Impact factor: 4.307

8.  Potent anti-tumor effect generated by a novel human papillomavirus (HPV) antagonist peptide reactivating the pRb/E2F pathway.

Authors:  Cai-ping Guo; Ke-wei Liu; Hai-bo Luo; Hong-bo Chen; Yi Zheng; Shen-nan Sun; Qian Zhang; Laiqiang Huang
Journal:  PLoS One       Date:  2011-03-15       Impact factor: 3.240

Review 9.  The pathologic diagnosis of mantle cell lymphoma.

Authors:  Shaoying Li; Jie Xu; M James You
Journal:  Histol Histopathol       Date:  2021-06-11       Impact factor: 2.303

10.  P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines.

Authors:  Nitesh P Shirsath; Sonal M Manohar; Kalpana S Joshi
Journal:  Mol Cancer       Date:  2012-10-18       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.